/
INAB
$1.11-$0.07 (-5.93%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$9.8M
10M shares
52-week range
$0.88 – $2.73
12% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Change$-278.49
IN8bio, Inc. Common Stock
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
www.in8bio.com- Employees
- 18
- IPO / List date
- Jul 30, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds INAB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in INAB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-06-06 | 1-for-30reverse |
Recent trades on TradeandTell
No one on the platform has traded INAB yet.
